Today: 17 May 2026

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus

Atara Biotherapeutics shares jumped 18% Monday after reports that FDA biologics chief Vinay Prasad will depart in April. The move follows the agency’s January rejection of Atara’s EBVALLO therapy for a rare blood cancer, which wiped out 56% of the stock’s value. Atara and partner Pierre Fabre have requested a Type A meeting with the FDA to revisit the decision. Atara ended 2025 with $8.5 million in cash.
9 March 2026
····
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Capricor Therapeutics shares jumped 7.6% to $30.01 after the company set March 12 for its quarterly and annual update, spotlighting its Duchenne muscular dystrophy therapy, deramiocel. An MDA conference abstract showed deramiocel met main goals in a 106-patient Phase 3 trial, with no imbalance in severe adverse events. The FDA rejected approval in July but later requested the full study report.
9 March 2026
·
Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

Nasdaq Partners With Kraken on Tokenized Stocks, Eyes 2027 Launch

Nasdaq announced plans for a tokenized shares framework and will partner with Payward, parent of crypto exchange Kraken, to build a gateway linking regulated stock markets to blockchain networks. The program is set to launch in the first half of 2027. Kraken will help distribute tokenized shares in Europe and other markets outside the U.S. The plan requires SEC approval and updated market infrastructure.
9 March 2026
·····
Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals, Inc. Buyout: Why Servier’s $2.5 Billion Ojemda Deal Matters Now

Day One Biopharmaceuticals shares traded at $21.24 Monday, just below Servier’s $21.50-per-share cash offer in a $2.5 billion takeover. The deal would give Servier Ojemda, the only U.S.-approved single-drug treatment for pediatric low-grade glioma, with 2025 sales of $155.4 million. The tender offer has not started and closing depends on shareholder response and U.S. antitrust clearance.
9 March 2026
W&T Offshore earnings: 2025 loss widens after delay as debt falls, offshore rule relief looms

W&T Offshore earnings: 2025 loss widens after delay as debt falls, offshore rule relief looms

W&T Offshore reported a preliminary 2025 net loss of $150.1 million, up from $87.1 million in 2024, as revenue dropped to $501.5 million and free cash flow plunged to $1.5 million. Average oil selling price fell to $64.09 a barrel, though production slightly increased. Year-end liquidity rose to $184.5 million, and net debt declined. The company warned results are unaudited and may change before its March 16 filing.
9 March 2026
·
Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals Holdings (RVPH) Starts 1-for-20 Reverse Split as Nasdaq Deadline Nears

Reviva Pharmaceuticals enacted a 1-for-20 reverse stock split early Monday to boost its share price and avoid a Nasdaq delisting. The company faces a March 27 deadline to meet the $1 minimum bid rule. Reviva is also seeking funding for a new Phase 3 trial of its schizophrenia drug after the FDA requested more data. Analyst Jason Kolbert downgraded the stock, citing unchanged fundamentals.
9 March 2026
·
uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure stock jolts higher again after FDA biologics chief set to exit

uniQure shares surged 34% to $14.27 in U.S. premarket trading Monday after news that FDA biologics chief Vinay Prasad will step down in April. The move follows a dispute over the agency’s demand for a new sham-surgery trial of uniQure’s Huntington’s gene therapy. The FDA has not agreed to approve the treatment based on current data. uniQure ended 2025 with $622.5 million in cash and investments.
9 March 2026
·
Oil Tops $100, Wall Street Futures Slide as Shock U.S. Jobs Data and Iran War Rattle Markets

Oil Tops $100, Wall Street Futures Slide as Shock U.S. Jobs Data and Iran War Rattle Markets

Brent crude topped $100 a barrel for the first time since 2022 as the U.S.-Israeli war with Iran disrupted the Strait of Hormuz and Gulf states cut oil output. S&P 500 futures fell 1.2% after a weak U.S. jobs report, while the VIX volatility index hit its highest since April 2025. Hundreds of tankers remained idle, and G7 finance ministers discussed a possible coordinated release of emergency oil reserves.
9 March 2026
·
3D Systems Corporation beats Q4 sales guidance, but weak Q1 outlook clouds recovery

3D Systems Corporation beats Q4 sales guidance, but weak Q1 outlook clouds recovery

3D Systems reported fourth-quarter revenue of $106.3 million, up 16% from the prior quarter and above its forecast, but still down 4% from a year earlier. Full-year revenue dropped 12% to $386.9 million, with a net income gain driven by asset sales and cost cuts. Healthcare Solutions rose 25% while Industrial Solutions fell 21%. The company expects a first-quarter revenue decline and continued losses.
9 March 2026
··
Aureus Greenway Holdings to Buy Powerus in Drone Pivot, With $9 Million Raise

Aureus Greenway Holdings to Buy Powerus in Drone Pivot, With $9 Million Raise

Aureus Greenway Holdings will acquire drone maker Powerus in an all-stock deal to take it public, renaming the combined company Powerus Corp and targeting a summer 2026 Nasdaq listing as PUSA. South Korea's KCGI committed to buy $50 million in Powerus stock, while Aureus arranged $9 million in new financing. The deal still requires SEC and shareholder approval. AGH shares rose 12.8% in premarket trading.
9 March 2026
·
US Stock Market Open Today: Oil Nears $120, Futures Slide and Fed Cut Bets Fade

US Stock Market Open Today: Oil Nears $120, Futures Slide and Fed Cut Bets Fade

U.S. stock futures fell sharply Monday as oil neared $120 a barrel, stoking inflation fears amid ongoing Middle East conflict. February jobs data showed a loss of 92,000 jobs and unemployment rising to 4.4%. Brent crude briefly hit $119, and the VIX touched its highest level since April 2025. G7 finance ministers plan to discuss a coordinated emergency oil release.
9 March 2026
··
Canada Stock Market Today: What to Know Before the TSX Open as Oil Shock Hits Banks, Miners

Canada Stock Market Today: What to Know Before the TSX Open as Oil Shock Hits Banks, Miners

Canada’s TSX index was set to open lower Monday, with futures down 0.92% after Brent crude touched $119.50 a barrel amid war involving Iran. The TSX had fallen 3.7% last week, its worst in over a month, as traders worried oil’s surge would fuel inflation. Wall Street futures dropped over 1%, and the VIX volatility index hit its highest since April 2025. Gold and base metals slipped, while financials faced scrutiny over condo appraisal practices.
9 March 2026
···
Silver Price Today: Why Silver Slipped to $84 as Dollar Surge and Oil Shock Rattle Markets

Silver Price Today: Why Silver Slipped to $84 as Dollar Surge and Oil Shock Rattle Markets

Spot silver fell 0.3% to $84.07 an ounce Monday after earlier losses of over 5%, as oil surged to $119.50 a barrel amid escalating conflict between the U.S., Israel, and Iran. Investors rushed to cash and the dollar strengthened, pushing back expectations for a U.S. rate cut to September or October. European and Asian markets also braced for more rate hikes as inflation fears mounted.
9 March 2026
·
Gold price today slides from $5,100 as oil shock lifts dollar, rate fears

Gold price today slides from $5,100 as oil shock lifts dollar, rate fears

Spot gold dropped 1.2% to $5,109.39/oz by 10:12 GMT Monday as a stronger dollar and surging oil prices pressured markets amid the U.S.-Israel-Iran war. Brent oil briefly hit $119.50 a barrel, reviving inflation fears and reducing bets on near-term U.S. rate cuts. Silver eased to $84.07/oz, while platinum and palladium also fell. U.S. stock futures and sterling declined as investors sought safety in the dollar.
9 March 2026
·
Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Stock Surges on Report Novo Nordisk Will Return to Sell Wegovy on Its Platform

Hims & Hers Health shares jumped premarket Monday after reports that Novo Nordisk will sell weight-loss drugs through its platform, with an announcement expected the same day. The move follows a recent patent dispute and comes as the FDA increases scrutiny of compounded GLP-1 drugs. Hims previously pulled a compounded Wegovy pill after FDA threats and a Novo lawsuit. The companies had partnered before but split last June over marketing concerns.
9 March 2026
···
Oil Prices Soar Above $100 as Iran War Chokes Supply and Governments Scramble

Oil Prices Soar Above $100 as Iran War Chokes Supply and Governments Scramble

Brent crude briefly hit $119.50 a barrel Monday, its highest since 2022, after conflict involving Iran disrupted Middle East oil supply and shipping. Iraq cut output by 70% at main southern fields, Bahrain declared force majeure, and Saudi Aramco offered rare tenders to fill gaps. Asian stocks fell as fuel costs surged. Brent later eased to around $107.80 as traders eyed possible reserve releases.
9 March 2026
··
1 … 148 149 150 151 152 … 1,947

Stock Market Today

  • Entegris (ENTG) Stock Pullback Highlights Valuation Nuances Amid Strong Growth
    May 17, 2026, 12:46 PM EDT. Entegris (ENTG) shares fell 4.4% in the latest session and about 10.8% over the past month, even as the stock shows year-to-date gains of 48.6% and a one-year return of 70.7%. The recent price dip raises questions about whether the stock remains undervalued. Its last close at $133.07 contrasts with a fair value estimate around $142.73, signaling a 6.8% undervaluation based on growth in advanced semiconductor materials. However, Entegris trades at a lofty price-to-earnings (P/E) ratio of 76.7, above peers' 70.1, indicating potential valuation risks if market sentiment shifts. Investors should weigh rising revenues and margins against risks like high $4 billion gross leverage and semiconductor demand cyclicality as they assess future gains.

Latest articles

Micron Faces Key Monday After Volatile Week

Micron Faces Key Monday After Volatile Week

17 May 2026
Micron Technology shares closed at $724.66 on Friday, down 6.6% after a record-setting week, but remain up nearly 154% for the year. The drop followed a broader market selloff, with the S&P 500 down 1.2% and the Nasdaq off 1.5% as Treasury yields rose. Micron recently began sampling 256GB DDR5 server memory modules to partners. Samsung faces a possible strike May 21, potentially affecting memory chip supply.
IREN Shares Slide 9% Friday as AI Bet Hits $3 Billion Mark

IREN Shares Slide 9% Friday as AI Bet Hits $3 Billion Mark

17 May 2026
IREN shares fell 9.35% to $52.94 Friday after closing a $3.0 billion convertible-note sale tied to its Nvidia-backed AI infrastructure expansion. The stock ended the week down about 13.5% from May 8. IREN’s new partnership gives Nvidia rights to buy up to 30 million shares at $70 each. The Nasdaq Composite dropped 1.5% Friday as tech stocks retreated.
SOFI heads into key week after tough session

SOFI heads into key week after tough session

17 May 2026
SoFi Technologies shares closed at $15.61 on Friday, down 2.56% for the day and 0.9% for the week. Trading volume reached about 50.1 million shares. The company maintained its 2026 outlook despite reporting record first-quarter results. Investors await SoFi’s May 19 presentation at J.P. Morgan’s technology conference.
Go toTop